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Impairment of gut mucosal immunity by the transplant process could facilitate translocation of commensal
bacteria and thereby augment the graft-versus-host response. To begin to assess the inﬂuence of gut mucosal
immunity on the development of acute graft-versus-host disease (GVHD), we conducted a prospective study
in 24 pediatric allogeneic hematopoietic cell transplant recipients, assessing 4 fecal markers of mucosal
immunity: calprotectin, soluble CD8 (sCD8), soluble intracellular adhesion molecule 1, and b-defensin-2. Stool
samples were collected prospectively on transplant days 0, þ5, þ10, and þ15 and analyzed by ELISA. Lower
levels on day þ5 (calprotectin and b-defensin-2) and day þ10 (calprotectin, b-defensin-2, and sCD8) were
associated with subsequent acute GVHD. The most striking difference was with calprotectin on day þ10.
Patients with levels below 424 mg/kg had an incidence of 77.8%, whereas those with levels above this
threshold had a cumulative incidence of 0% (P ¼ .002). Relative defects in gut mucosal immunity may be
important in the pathogenesis of acute GVHD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The gut and its ﬂora are central to the pathogenesis of
acute graft-versus-host disease (aGVHD) [1]. In the triphasic
model of aGVHD conceptualized by Ferrara and Antin [2], the
process is initiated (phase I) by damage to the mucosal bar-
rier induced by conditioning, permitting translocation of
commensal bacteria and stimulating, in turn, inﬂammation.
This inﬂammation primes and ampliﬁes the host-targeted
response of donor T cells.
It is possible, however, that the bacterial translocation,
which is central to this model, is not simply the result of the
disruption of the physical barrier. The weakening of mucosal
immunity by the transplant process could also be important.
The gut’s mucosal immunity is broadly compromised during
hematopoietic stem cell transplantation (HSCT); host neu-
trophils and intraepithelial lymphocytes, important weapons
against microbial invasion of the mucosa, are both lost
through the effects of conditioning [3,4]; damage to the
epithelial cells, which not only provide a physical barrier but
also direct the transmigration of leukocytes to the luminal
surface and secrete antimicrobial peptides, also occurs [5]. In
this way, the pathogenesis of aGVHD could resemble theedgments on page 1059.
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14.03.012pathogenesis of Crohn’s disease, where more limited defects
in mucosal immunity appear to be important [6].
The role of defective mucosal immunity in the patho-
genesis of aGVHD could be assessed in a preliminary and
noninvasive way by using fecal biomarkers. It might also be
possible to exploit any differences in fecal biomarker levels
observed to be associatedwith the development of aGVHD to
devise an approach for detecting aGVHD before clinical
manifestations emerge. Fecal markers have been established
as valuable tools in other settings. Clinically, they are used in
the management of a variety of gastrointestinal illnesses,
including inﬂammatory bowel disease [7] and pancreatic
insufﬁciency [8]. They are also being used increasingly as
research tools for a variety of diseases, including colon cancer
[9]. The potential of fecal biomarkers in aGVHD is beginning
to be assessed, with 3 groups recently reporting results of
research using markers for diagnosing aGVHD and for pre-
dicting its response to therapy [10-12].
We conducted a prospective, longitudinal study in pedi-
atric allogeneic HSCT recipients. We assessed 4 fecal
markers: calprotectin, soluble CD8 (sCD8), soluble intracel-
lular adhesion molecule 1 (sICAM-1), and bedefensin-2.
Calprotectin, an antimicrobial protein released from neu-
trophils [13], has been extensively studied in inﬂammatory
bowel disease and is now routinely used as a diagnostic test
in this setting [14]. b-Defensin-2, an antimicrobial peptide
secreted by gut mucosal epithelial cells [15], is now also
being examined in inﬂammatory bowel disease [16]. CD8 is
released from the surface of activated CD8 þ T cells [17],
which form the majority of intraepithelial lymphocytes [18].
Although not previously used as a stool marker before, we
Table 1
Patient Characteristics (N ¼ 24)
Characteristic Value





Acute lymphoblastic leukemia 7 (29.2%)
Acute myeloid leukemia/MDS 11 (45.8%)






HLA matched related marrow 7 (29.2%)
Mismatched related marrow 1 (4.2%)
Unrelated marrow 6 (25%)
Unrelated cord blood, single 6 (25%)







MDS indicates myelodysplastic syndrome.
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sCD8 level predict aGVHD [19]. sICAM-1 is released from the
surface of epithelial cells (as well as endothelial cells) during
inﬂammation [20]. ICAM-1 is expressed on the luminal sur-
face of gut epithelium, where it assists in the transmigration
of neutrophils [21]. Although it also has not previously been
used as a stool marker, elevations in its plasma levels have
been associated with aGVHD [22].
METHODS
Subjects
The institutional review boards of Emory University School of Medicine
and Children’s Healthcare of Atlanta approved the study protocol. Patients
under age 21 years undergoing an allogeneic HSCT at Children’s Healthcare
of Atlanta for a malignant or nonmalignant disease were eligible. Patients
with a condition deemed to have the potential to raisemarker levels, such as
inﬂammatory bowel disease or other pre-existing gastrointestinal disease,
active infection, treatment-unresponsive hemophagocytic lymphohistiocy-
tosis, treatment-unresponsive hematologicmalignancy, or high risk for graft
rejection, were ineligible. Midway through the study, in an effort to capture
a sufﬁcient number of patients developing aGVHD, enrollment was
restricted to those receiving myeloablative conditioning and alternative
donor transplants. Patients were followed for aGVHD [23] and infection
through day þ100.
Biomarkers
Stool sampleswere collected prospectively on transplant days 0,þ5,þ10,
and þ15. The stool samples were analyzed using commercially available
ELISA kits for calprotectin (Buhlmann Laboratories, Schönenbuch,
Switzerland), b-defensin-2 (Immundiagnostik, Bensheim, Germany), sCD8
(Bender MedSystems, Vienna, Austria), and sICAM-1 (R&D Systems,
Minneapolis, MN). Solution was extracted from the stool samples, using a
commercial kit (Buhlmann Laboratories), and then aliquoted and stored at
e80C. All testingwas performed according tomanufacturers’ speciﬁcations.
Statistical Analysis
Cut-offs in biomarker levels were determined using recursive parti-
tioning. The cumulative incidences of aGVHD for patients with levels above
and below the thresholds were compared using the log rank test. The po-
tential screening test characteristics of the markers were assessed using a
receiver-operating characteristic curve analysis. An area under a receiver-
operating characteristic curve was considered statistically signiﬁcant if the
conﬁdence intervals around the estimate did not include .5, the value ex-
pected for a nondiscriminating test. Statistical analyses were performed
using SPSS version 18 (SPSS Inc., Chicago, IL).
RESULTS
Twenty-four patients were enrolled between November
2008 and October 2010 (Table 1). All patients survived
through at least day þ30 and could be assessed for aGVHD.
The median patient age was 10 years (range, 1 to 23 years),
with 16 boys and 8 girls. Seventeen patients received an
unrelated or mismatched related transplant, and 20 patients
were transplanted for an acute leukemia or myelodysplastic
syndrome. The rest had nonmalignant diseases. Thirteen
patients received marrow grafts, and the rest received single
or double cord blood grafts. All but 1 patient received mye-
loablative conditioning. All patients received T cellereplete
grafts with calcineurin inhibitorebased GVHD prophylaxis.
aGVHD of any grade was diagnosed in 10 patients. The
median day of diagnosis was day þ25 (range, 19 to 49) in 10
patients. All but 1 patient had biopsies to conﬁrm their di-
agnoses. The maximal grade of aGVHD attained by day þ100
was grade I in 1 patient, grade II in 5 patients, grade III in 2
patients, and grade IV in 2 patients. Two patients had disease
that was initially steroid-refractory and a third had a steroid-
refractory recurrence. All 3 of these patients died. Seven
patients had gastrointestinal involvement, and all but 1 had
involvement of the lower tract. One patient with steroid-
refractory disease was diagnosed with cytomegalovirusenteritis by endoscopic biopsy at day þ72. None of the other
patients was diagnosed with gastrointestinal infections.
For calprotectin and b-defensin-2, levels below the
threshold on day þ5 and day þ10 were associated with a
higher cumulative incidence of aGVHD (Table 2). For sCD8,
levels above the threshold on day 0 and below the threshold
day þ10 were associated with aGVHD. For sICAM-1, none of
the results was statistically signiﬁcant. There was, however, a
trend on day 0 with levels below the threshold associated
with aGVHD. The most striking difference was with calpro-
tectin on day þ10. Patients with levels below 424 mg/kg had
an incidence of 77.8%, whereas those with levels above this
threshold had a cumulative incidence of 0% (P ¼ .002)
(Figure 1). The median calprotectin levels at this juncture
were 188 mg/kg (range, 64 to 294 mg/kg) in patients who
went on to develop GVHD and 655 mg/kg (range, 147 to
1953 mg/kg) in those who did not.
The receiver-operating characteristic curve analysis
yielded statistically signiﬁcant results for calprotectin and
b-defensin-2 (Table 2). The highest area under the curve was
obtained for calprotectin on day þ10 (.89, 95% conﬁdence
interval, .72 to 1). The corresponding sensitivity, speciﬁcity,
positive predictive value, and negative predictive value were
1, .8, .78 and 1, respectively.
Although we did not consistently collect samples beyond
day þ15, we obtained samples in 6 patients at the time of
diagnosis. We obtained a second sample in 1 of these 6, who
initially had a complete response to steroids, during a severe
and steroid-refractory recurrence. Finally, we obtained a
sample in a seventh patient with steroid-refractory disease
10 days into treatment. These 8 calprotectin levels ranged
from 102 to 4312 mg/kg (median, 568 mg/kg). The 3 highest
levels, 2077, 2681, and 4312 mg/kg, were from the 3 samples
obtained during steroid-refractory disease. The highest level
obtained from a sample during steroid-responsive disease
was 745 mg/kg. No such pattern was noted for the 3 other
markers (data not shown).
Table 2







P AUC (95% CI)a
Below Above
Calprotectin 0 381 (mg/kg) 23 60% 12.5% .054 .61 (.37-.85)
5 207 21 75% 23.1% .017 .74 (.52-.96)
10 424 17 77.8% 0% .001 .89 (.72-1)
15 174 19 28.6% 54.5% .415 .46 (.18-.74)
sCD8 0 162 (U/mL) 23 28.6% 66.7% .033 .42 (.16-.67)
5 133 21 20% 50% .230 .44 (.18-.71)
10 177 17 66.7% 12.5% .04 .7 (.43-.97)
15 153 19 66.7% 33.3% .258 .62 (.34-.90)
sICAM-1 0 1.5 (ng/mL) 23 61.5% 20% .062 .65 (.4-.9)
5 1.4 21 55.6% 33.3% .324 .49 (.22-.76)
10 1.5 17 55.6% 25% .320 .66 (.38-.94)
15 1.7 19 53.8% 20% .267 .66 (.41-.92)
b-Defensin-2 0 149 (ng/mL) 23 56.3% 14.3% .084 .62 (.39-.86)
5 91 21 70% 18.2% .028 .75 (.53-.97)
10 144 17 41.2% 0% .044 .71 (.47-.96)
15 d 19
AUC indicates area under curve; d, no cut-off could be determined at this time point.
a Derived from receiver-operating characteristic curve analysis.
K.J. August et al. / Biol Blood Marrow Transplant 20 (2014) 1056e10731058DISCUSSION
This prospective study of pediatric allogeneic HSCT re-
cipients demonstrates for the ﬁrst time that it is feasible to
measure fecal markers of mucosal immunity in the early,
pre-engraftment phase of allogeneic HSCT. Notably, despite
the severe reduction in neutrophils and in lymphocytes
produced by intensive conditioning early post-transplant,
calprotectin, a marker derived largely from neutrophils,
and sCD8, a marker likely to be derived from intraepithelial
lymphocytes, both remained detectable.
This study also demonstrates for the ﬁrst time that
early post-transplant changes in 3 markersdcalprotectin,
b-defensin-2, and sCD8dare predictive of aGVHD. Impor-
tantly, in all but 1 case, lower rather than higher levels were
predictive. Given the importance of the role of the gut’s
commensal ﬂora in the pathogenesis of aGVHD [24-26], thisFigure 1. Cumulative incidence of grades I to IV aGVHD based on day of cal-
protectin stool levels.observation raises the possibility that deﬁcient mucosal im-
munity predisposes patients to aGVHD by facilitating bac-
terial translocation. Given the limitations inherent in
observational clinical studies, such as ours, however, it would
be inappropriate for us to draw this causal inference directly
from our ﬁndings. We cannot discount other possible ex-
planations for other ﬁndings; for instance, it may be that
incipient GVHD is the cause of, rather than the product of,
some of these abnormalities. The recent demonstration in
an animal model that GVHD injures Paneth cells, which
secrete a-defensins and other antimicrobial peptides, is
consistent with this possibility [27]. Further research using
experimental approaches, then, is needed to explore the
relationship betweenweakened antimicrobial immunity and
aGVHD.
At ﬁrst glance, our results may seem to diverge from the
results of 3 recently reported studies assessing calprotectin’s
potential for diagnosing aGVHD and predicting response to
steroid therapy [10-12]. Two of these studies demonstrated
that patients diagnosed with gastrointestinal aGVHD have
higher levels of calprotectin [10,11]. The third demonstrated
that higher levels of calprotectin at diagnosis are associated
with steroid-refractory disease [12]. Although the focus of our
effort was on pre-engraftment levels of markers, we did assess
fecal samples at or after diagnosis in 7 patients and observed
veryhigh levels in steroid-refractorydisease. This suggests that
even if early, pre-engraftment deﬁciencies of calprotectin may
predispose patients to developing aGVHD, once severe aGVHD
develops, fecal calprotectin levels rise markedly.
Most of the cases of aGVHD in our study involved the
gastrointestinal tract. Our sample size was not large enough
to permit us to assess whether these markers are predictive
of aGVHD in the absence of gastrointestinal involvement.
Finally, our ﬁndings also suggest that the test character-
istics of 1marker, calprotectin, may be robust enough for it to
be used clinically for the early detection of aGVHD. It could
thus form the basis for the development of pre-emptive
approaches to treating GVHD. Before this step is taken,
however, our ﬁndings need to be validated in a larger study
that includes adults as well as children. An appealing feature
of calprotectin is that, unlike many other biomarkers of
GVHD now being tested, it is already widely available in
K.J. August et al. / Biol Blood Marrow Transplant 20 (2014) 1056e1073 1059clinical laboratories, because it is approved for use in
inﬂammatory bowel disease (www.fda.gov).
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